ClinicalTrials.gg
CompletedNCT06055023Updated Apr 3, 2025

Phase I Clinical Study of ZL-82 Tablets

A Phase 1 interventional study of ZL-82 12.5mg and ZL-82 25mg in Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease - IBD1, sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Apr 2023, registered Sep 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Enrollment
145th of 217
69 · median 134
Started
2023
with 18 others
Phase 1
54 of 249
20 open now
Registered
172nd of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 145th largest by enrollment of the 217 interventional ones that give a count, is one of 19 that started in 2023, is one of 54 in phase 1, and was the 172nd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

ZL-82 is an oral janus kinase (JAK) inhibitor. In vitro biological mass spectrometry identification test proves that ZL-82 can selectively and irreversibly inhibit JAK3. It has obvious safety advantages, with a wide therapeutic window and controllable cardiotoxicity. This is also demonstrated from preliminary GLP-conditions of acute toxicity in SD rats and Beagle dogs. Results of 4-week long-term toxicity in Beagle dogs also support this notion. Therefore, ZL-82 has the potential to treat rheumatoid arthritis. It Used to relieve and heal swelling, pain, stiffness, and limited mobility that may be caused by rheumatoid arthritis.The drug is intended to be used in patients with RA to relieve and heal swelling, pain, stiffness, and limited mobility that may be caused by rheumatoid arthritis.

Pharmacodynamic studies show that ZL-82 has a strong inhibitory effect on JAK3 with IC50 of 2.8 nM, and has no obvious inhibitory effect on JAK1, JAK2 and TYK2. Compared with the similar drug Tofacitinib, its inhibitory effect on JAK3 subtype is 1nM, but its inhibition IC50 for JAK1 subtype and JAK2 subtype are 112nM and 20nM, respectively.and its selectivity is 100-fold and 20-fold, respectively.Also, the selectivity multiples of ZL-82 were 100-fold and 20-fold than tofacitinib , respectively, which indicates that ZL-82 is more selective than the marketed Tofacitinib.This allows ZL-82 to precisely inhibit JAK kinase and block a series of cytokines in the downstream signaling pathway. And show significant effect on rheumatoid arthritis.

The experimental results showed that in DTH and CIA models, 25, 50, 75, and 100 mg/kg of this variety could dose-dependently inhibit joint swelling in mice.

Objectives of Study

Main Purpose:

  1. To evaluate the tolerability, safety and pharmacokinetic characteristics of a single oral dose of ZL-82 tablets in healthy adult subjects;
  2. To explore the effect of eating on the PK of oral ZL-82 tablets in healthy adult subjects;
  3. To evaluate the tolerability, safety and pharmacokinetics of ZL-82 tablets after multiple oral administration in healthy adult subjects.
03

Conditions studied

  • Rheumatoid Arthritis (RA)
  • Inflammatory Bowel Disease - IBD1
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects, regardless of gender, 18 to 45 years old (including 18 and 45 years old)
  • The weighing of male subjects ≥ 50kg, female subjects ≥ 45kg, and a (BMI) between 19 and 25kg/m2 (including boundary values)
  • The medical history, physical examination, laboratory examination items and various tests and tests related to the trial before enrollment were normal or abnormal without clinical significance, and the clinical research doctor judged that they were qualified.
  • Be able to understand the form, voluntarily participate in the trial and sign the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Allergic constitution, such as those who are known to be allergic to two or more substances, or those who are known to be allergic to JAK inhibitors or to the contained in the test drug
  • and/or AST>1×, TIB>1×ULN, GGT>1×ULN; Scr>1×ULN
  • Major surgery within the 3 months prior to the trial or planning to undergo surgery during the trial
  • Acute illness within 2 weeks prior to trial
  • Have any serious diseases such as cardiovascular system, digestive system, urinary system, respiratory system, nervous system, immune system, endocrine system, malignant tumor, mental illness, etc.
  • History of dysphagia or any gastrointestinal disease (or gastrointestinal resection, etc.) affecting drug absorption
  • antibody, Treponema pallidum antibody, surface antigen and antibody test are positive
  • Positive urine drug screen (including morphine, methamphetamine, ketamine, MDMA, THC)
  • Systolic blood pressure>140mmHg or diastolic blood pressure>90mmHg during the screening period;
  • Blood donation or blood loss ≥400mL within 3 months, or blood transfusion; blood donation or blood loss ≥200mL within 1 month;
  • Have special requirements for diet or cannot comply with the unified diet and corresponding regulations of the research center
  • Alcoholics (alcoholism refers to drinking 60-degree white wine ≥10.5L or red wine ≥3.5L per week for more than 5 years), drinking a lot of coffee-containing beverages (more than 8 cups per day, 1 cup = 250ml) or heavy smoking (average > 20 sticks/day);
  • Have used any prescription drugs (JAK inhibitors, etc.) that may have an effect on the test drug within 2 weeks;
  • 4 weeks (28 days) before enrollment, strong inducers of liver metabolic enzymes was limit. ( such as omeprazole, barbiturates, carbamazepine, aminoglutamine, griseofulvin, carbamazepine, Phenytoin, Gluter, Rifampicin, Sulfinpyrazone, Roxithromycin, etc. )
  • Participate in clinical trials of other drugs or medical devices as subjects within 3 months
  • Women who are pregnant or breastfeeding or women of childbearing age who have had unprotected sex with their partner within 14 days before the test;
  • The subjects or their partners are unwilling to use non-drug measures (such as total abstinence, condoms, IUDs, ligation, etc.) for contraception during the trial, or the subject and his partner has a pregnancy plan within 6 months of signing the ;
  • Not suitable to participate in the trial according to the judgment of the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    ZL-82

    1 case,The starting dose,Take the medicine once on D1 ,D1 through 7.

    Drug: ZL-82 12.5mg · Drug: ZL-82 25mg · Drug: ZL-82 50mg · Drug: ZL-82 100mg · Drug: ZL-82 200mg · Drug: ZL-82 300mg · Drug: ZL-82 450mg · Drug: ZL-82 600mg

  • Placebo comparator
    zL-82 placebo group

    1 case,The starting dose,Take the medicine once on D1,D1-7.

    Drug: zL-82 placebo 12.5mg · Drug: ZL-82 placebo 25mg · Drug: ZL-82 placebo 50mg · Drug: ZL-82 placebo 100mg · Drug: ZL-82 placebo 200mg · Drug: ZL-82 placebo 300mg · Drug: ZL-82 placebo 450mg · Drug: ZL-82 placebo 600mg

Interventions

  • DrugZL-82 12.5mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 25mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 50mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 100mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 200mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 300mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 450mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 600mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugzL-82 placebo 12.5mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 placebo 25mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 placebo 50mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 placebo 100mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 placebo 200mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 placebo 300mg

    1 case,The starting dose,Take the medicine once on D1,D1-7. Edit

  • DrugZL-82 placebo 450mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

  • DrugZL-82 placebo 600mg

    1 case,The starting dose,Take the medicine once on D1,D1-7.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of ZL-82:Cmax

    Estimation of maximum observed plasma concentration

    Time frame: 24hours

  2. Pharmacokinetics (PK) of ZL-82:Tmax

    Estimation of time to reach Cmax

    Time frame: 24hours

  3. Pharmacokinetics (PK) of ZL-82:AUC0-24h

    Estimation of AUC from time zero to the last measured time point

    Time frame: 24hours

  4. Pharmacokinetics (PK) of ZL-82:AUC0-∞

    Estimation of AUC from time zero extrapolated to infinity

    Time frame: 24hours

  5. Pharmacokinetics (PK) of ZL-82:Vd

    Estimation of apparent volume of distribution

    Time frame: 24hours

  6. Pharmacokinetics (PK) of ZL-82:t1/2

    Estimation of terminal elimination half-life

    Time frame: 24hours

  7. Pharmacokinetics (PK) of ZL-82:CLz/F

    Estimation of clearance when dosed orally

    Time frame: 24hours

  8. Pharmacokinetics (PK) of ZL-82:Vz/F

    Estimation of apparent volume of distribution when dosed orally

    Time frame: 24hours

  9. Pharmacokinetics (PK) of ZL-82:Kel

    Estimation of the elimination rate constant of a drug in the body

    Time frame: 24hours

07

Study locations

1 site
  • Affiliated Hospital of Guizhou Medical University
    Guizhou, GuiYang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jan 2024, 9 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 9 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Sep 26, 2023
StartActual
Apr 9, 2023
Primary completionActual
Jan 28, 2024
CompletionActual
Jun 13, 2024
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06055023
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Apr 9, 2023
Primary completion
Jan 28, 2024
Completion
Jun 13, 2024
Last update
Apr 3, 2025

Study contacts

Chen Lijuan, doctor
study chair · West China Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion